Bristol Myers nabs long-sought FDA nod for Celgene's MS drug ozanimod, but pandemic delays launch

25th March 2020 Uncategorised 0

Bristol Myers Squibb’s $74 billion acquisition of Celgene last year hinged on a few of Celgene’s late-stage pipeline hopefuls, including multiple sclerosis treatment ozanimod. Now that the drug has finally reached the finish line, it will face a range of challenges, starting with a delayed launch due to COVID-19.

More: Bristol Myers nabs long-sought FDA nod for Celgene's MS drug ozanimod, but pandemic delays launch
Source: fierce